personal accountability, maladaptive coping and numerous time-consuming demands may negatively affect their own physical and mental health, and this in turn may negatively affect the health outcomes of AYA patients. 2 – 7 , 16 – 20 , 29 , 30 Parents’ self
Search Results
Randomized Trial of a Supportive Psychotherapy for Parents of Adolescents and Young Adults With Hematologic Malignancies
Michael Koehler, Susanne Hoppe, Siegfried Kropf, Anke Lux, Rainer Bartsch, Bernhard Holzner, Juergen Krauter, Axel Florschütz, Kathleen Jentsch-Ullrich, Joerg Frommer, Hans-Henning Flechtner, and Thomas Fischer
NCCN Guidelines Updates: Discontinuing TKI Therapy in the Treatment of Chronic Myeloid Leukemia
Neil P. Shah
response levels on outcome. Findings showed that no significant difference was observed for relapse according to depth of molecular response at discontinuation. Data from Mahon et al. 2 Relaxing the threshold, as well as the duration of DMR, has made TKI
CLO22-052: A Tale of Two Schedules: A Study of the Efficacy and Toxicity Outcomes of Extended Durvalumab Dosing in Patients with Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)
Lilian Hanna, Gordon Taylor Moffat, Wilma Hopman, Pierre-Olivier Gaudreau, and Andrea S. Fung
Background : The addition of durvalumab following chemoradiation in unresectable Stage III NSCLC has led to improved cancer outcomes. The schedule of administration has largely been determined by pharmacokinetic studies with a paucity of data
Mobile Technology-Based (mLearning) Intervention to Enhance Breast Cancer Clinicians' Communication About Sexual Health: A Pilot Trial
Jennifer Barsky Reese, Lauren A. Zimmaro, Sharon L. Bober, Kristen Sorice, Elizabeth Handorf, Elaine Wittenberg, Areej El-Jawahri, Mary Catherine Beach, Antonio C. Wolff, Mary B. Daly, Brynna Izquierdo, and Stephen J. Lepore
communication skills development, 22 – 24 and social cognitive theory, which emphasizes individuals’ beliefs (ie, self-efficacy and outcome expectancies) as critical processes underlying successful behavioral interventions. 22 , 25 – 28 We adapted the
Additional Abstracts from the NCCN 21st Annual Conference: Advancing the Standard of Cancer Care™
interventions to minimize distress and improve patient quality of life. AB2016-29. Treatment Outcomes in Patients With Metastatic Neuroendocrine Tumors: Retrospective Analysis of a Community Oncology Database Maxine D. Fisher, PhD a ; Sonia Pulgar, MPH b
HSR21-073: Febrile Neutropenia Outcomes Among Patients With Breast Cancer and Non-Hodgkin’s Lymphoma Receiving Pegfilgrastim Prophylaxis: A Real-World Analysis of Commercial and Medicare Claims From 2017-2018
Weijia Wang, Edward Li, Kim Campbell, and Ali McBride
Introduction: Febrile neutropenia (FN) is a major dose-limiting toxicity of myelosuppressive chemotherapy that can result in hospitalization, dose reductions or treatment delays and compromised clinical outcomes. National Comprehensive Cancer
HSR22-141: Treatment Patterns and Clinical Outcomes Among Metastatic Non-Small Cell Lung Cancer Patients Without Actionable Genomic Alterations (AGAs) Previously Treated With Platinum-Based Chemotherapy and Immunotherapy
Jerome H Goldschmidt, Anupama Vasudevan, Michelle Silver, Jackie Kwong, and Elizabeth Marrett
1. Clinical Outcomes by Subsequent Treatment *Other sTx group not shown due to small sample size
Counterpoint: Implementing Population Genetic Screening for Lynch Syndrome Among Newly Diagnosed Colorectal Cancer Patients—Will the Ends Justify the Means?
Michael J. Hall
with Lynch in the United States population and, more importantly, 2) to effectively improve health outcomes for patients with CRC and their relatives, because of a paucity of information on real-life access barriers, educational gaps, and patient
Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study
Baijun Dong, Liancheng Fan, Bin Yang, Wei Chen, Yonghong Li, Kaijie Wu, Fengbo Zhang, Haiying Dong, Huihua Cheng, Jiahua Pan, Yinjie Zhu, Chenfei Chi, Liang Dong, Jianjun Sha, Lei Li, Xudong Yao, and Wei Xue
alterations, especially those involving DDR genes, can predict the clinical outcomes of Chinese patients with mCRPC following specific treatments remains to be fully elucidated. Routine sampling of bone and other metastatic tissues in patients with mCRPC is
